Elvitegravir (EVG formerly GS-9137) is a drug used for the treatment of HIV infection. It acts as an integrase inhibitor. It was developed by the pharmaceutical company Gilead Sciences which licensed EVG from Japan Tobacco in March 2008. The drug gained approval by U.S.
This page contains content from the copyrighted Wikipedia article "Elvitegravir"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
